MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
MSD in the UK
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
Shingles
Shingles /
Therapy Areas /
Root /

Shingles

Prescribing Information

msd_zostavax_therapy_about-nip

Shingles National Immunisation Programme   >

What is the Shingles National immunisation Program? Who is eligible? Patient eligibility check tool
msd_zostavax_therapy_complications-of-shingles

About Shingles   >

Incidence of shingles Complications Treatment of Shingles and Post Herpetic Neuralgia
msd_zostavax_therapy_optimise-your-practice

Optimising you practice   >

How to find your patients Setting up your practice Practice support materials
msd_zostavax_therapy_zostavax-logo

Zostavax   >

Prescribing information Adverse events More about Zostavax

ZOSTAVAX is indicated for

  • Prevention of herpes zoster ("zoster" or shingles) and herpes zoster-related post-herpetic neuralgia (PHN) in the UK
  • Immunisation of individuals who are 50 years of age or older

Supporting documentation

Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-CIN-00208 | Date of Preparation: June 2020